Testing for Multiple Biomarkers at a Time Can Increase Early Detection of OC

Testing for Multiple Biomarkers at a Time Can Increase Early Detection of OC
Testing for additional biomarkers along with the well-known biomarker CA125 can improve the detection of early-stage ovarian cancer, a new study shows. The blood-based assay could significantly improve patient survival if ovarian cancers are identified earlier. The study, “Simultaneous Measurement of 92 Serum Protein Biomarkers for the Development of a Multi-Protein Classifier for Ovarian Cancer Detection,” was published in the journal Cancer Prevention Research. Ovarian cancer is the one of the leading causes of cancer-related death in women around the world, mostly because women are diagnosed at later stages, when the chances of cure are low. “In the earliest stages, ovarian cancer can be treated with a 5-year survival rate of more than 90%. However, in later stages, the 5-year survival rate decreases to about 30%,” Amy P.N. Skubitz, PhD, researcher at the University of Minnesota, said in an interview with Healio HemOnc Today. There is currently no accurate test to screen for ovarian cancer in the general population. Two ovarian cancer biomarkers — CA125 and HE4 — can help monitor recurrence of ovarian cancer. However, neither can adequately detect ovarian cancer when used alone for early-st
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *